Skip to main content
BioPorto logo

BioPorto — Investor Relations & Filings

Ticker · BIOPOR ISIN · DK0011048619 LEI · 5299004SWFL5JAN4W830 CO Manufacturing
Open in API
Filings indexed 788 across all filing types
Latest filing 2024-01-09 Board/Management Inform…
Country DK Denmark
Listing CO BIOPOR

About BioPorto

https://bioporto.com/

BioPorto is an in vitro diagnostics company specializing in actionable biomarkers to improve kidney health. The company's primary focus is the development and commercialization of diagnostic tests based on the Neutrophil Gelatinase-Associated Lipocalin (NGAL) biomarker for the early risk assessment and diagnosis of acute kidney injury (AKI). Its product portfolio includes The NGAL Test™ for clinical use and the FDA-cleared ProNephro AKI (NGAL) test for pediatric applications. These tools enable clinicians to detect kidney damage earlier than traditional methods, facilitating timely intervention. BioPorto also provides a range of NGAL ELISA kits and antibodies for preclinical and clinical research settings.

Recent filings

Filing Released Lang Actions
Board/Management Information 2024
Board/Management Information Classification · 100% confidence The document explicitly announces changes to the Executive Management, specifically the stepping down of the CEO and the appointment of an interim CEO. This content directly aligns with the definition of Board/Management Information (MANG). Although it mentions future financial guidance publication, the primary subject is the management transition, not the release of the financial report itself (which would suggest RPA or ER/IR). The document is a formal announcement, not a full annual or interim report.
2024-01-09 English
BioPorto implements changes to the Executive Management.
Board/Management Information Classification · 100% confidence The document is an official announcement from BioPorto A/S regarding changes to its Executive Management, specifically the departure of the CEO and the appointment of an interim CEO. This content directly matches the definition for Board/Management Information (MANG), which covers announcements of changes in a company's board or senior management.
2024-01-09 English
Director's Dealing 2023
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Managers’ transactions' and details a transaction made by a person closely associated with a member of the Board of Directors, referencing Article 19 of Regulation (EU) No. 596/2014. This regulation pertains to transactions by persons discharging managerial responsibilities (PDMRs). The filing category 'Director's Dealing' (DIRS) specifically covers reports of personal share transactions by company directors and executives (insider trades). Although the document structure is similar to a regulatory filing announcement, the content is highly specific to insider trading disclosure, making DIRS the most appropriate classification over the general RNS.
2023-12-09 English
Managers’ transactions
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction involving shares of BioPorto A/S by a person closely associated with a member of the Board of Directors. It explicitly references 'Managers' transactions' and provides details required by EU Regulation 596/2014, such as the name of the person, the nature of the transaction (sale of shares), price, volume, and date. This fits the definition of a Director's Dealing (DIRS) filing.
2023-12-09 English
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a press release dated December 7, 2023, titled "BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States." It announces a significant regulatory achievement (FDA clearance) and discusses future commercialization plans and financial guidance context. This type of announcement, which is a formal update on a specific event (regulatory approval) rather than a comprehensive periodic report (like 10-K or IR), fits best under the general category of regulatory or corporate announcements. Since it is not a standard earnings release (ER), a management discussion (MDA), or a specific capital event (CAP), and it is a formal announcement distributed via a wire service (indicated by the structure and footer), it is classified as a general Regulatory Filing (RNS). It is not an announcement *about* a report (RPA), but the report/news itself.
2023-12-07 English
BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years
Regulatory Filings Classification · 95% confidence The document is a corporate announcement regarding the FDA 510(k) clearance of a medical product (ProNephro AKI). It is a press release/regulatory announcement issued by BioPorto A/S. Since it does not fit into specific categories like financial reports, proxy statements, or director dealings, and serves as a general corporate update on business operations and regulatory milestones, it falls under the 'Regulatory Filings' (RNS) category.
2023-12-07 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.